Tamoxifen

A prescription SERM approved for treatment and risk reduction of certain breast cancers. It is sometimes misused after anabolic-steroid exposure to counter suppression, but that use is unapproved and no standardized recovery regimen is established.

Tamoxifen is a selective estrogen receptor modulator (SERM): it blocks the estrogen receptor in some tissues while acting like estrogen in others. That tissue selectivity is the whole point. In the breast it is anti-estrogenic (its cancer use). At the hypothalamus and pituitary it blocks the estrogen feedback that normally suppresses LH and FSH, so those signals rise and the testes are told to produce more testosterone — the basis of its use in male hormone recovery and in gynecomastia. Crucially it lowers estrogen SIGNALLING without lowering circulating estradiol the way an aromatase inhibitor does, so it does not carry the same bone-density cost.

Decades of oncology data. No randomised evidence establishes tamoxifen as a treatment for steroid-induced hypogonadism or proves it restores fertility or endogenous testosterone; the recovery use rests on survey and retrospective reports, not controlled trials.

• Oncology evidence is vast and high quality — decades of large randomised trials in breast cancer prevention and treatment.
• In men, studies show it raises LH, FSH and testosterone by relieving estrogen feedback, and it has trial support for reducing gynecomastia, including steroid-associated gynecomastia. For restarting a steroid-suppressed axis specifically, there is no randomised evidence — the use is real but unproven.
• For the specific job of restarting the hormonal axis after suppressive steroid use, the human evidence is real but thinner and mostly short-term; it is a legitimate clinical tool used off-label, not a guaranteed reset.

An oral drug with a long half-life (its active metabolites persist for days to over a week), so it reaches steady state slowly and clears slowly. It is metabolised by the liver via CYP2D6 into endoxifen, its main active form — which is why anything that blocks CYP2D6 blunts it, and why the DIM interaction (which lowers endoxifen) matters.

Reported risks include thromboembolism and stroke (the serious ones, especially with other risk factors), cataracts and other ocular effects, mood and libido changes. New visual symptoms require prompt medical assessment. Recovery of a suppressed axis is not guaranteed regardless of what is taken.

• Anyone with a personal or family history of blood clots, or other thrombosis risk factors — this is the headline danger.
• Anyone on a CYP2D6-inhibiting antidepressant, where it may not work as intended.
• Anyone treating a non-estrogenic side effect with it (it will not touch prolactin-driven gynecomastia from nandrolone or trenbolone).
• Anyone who would be better served by a clinician-run recovery, which is most people attempting it alone.

• CYP2D6 inhibitors (some SSRIs, notably paroxetine and fluoxetine) reduce conversion to endoxifen and blunt the effect — a well-documented and clinically important interaction.
• DIM lowers tamoxifen metabolite levels including endoxifen (randomised-trial evidence) — a real interaction with the supplement, not a footnote.
• Anastrozole levels fall when the two are combined, one reason they are not simply stacked.
• Anticoagulants — the combined effect on clotting compounds tamoxifen's own thrombotic risk.

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

• LH, FSH and total testosterone — the axis it is meant to move; the point of a recovery attempt is to see these rise.
• Symptoms of the estrogenic actions it keeps: it does not crash estradiol, so estrogen-deficiency symptoms are not the concern; mood and vision changes occasionally reported are.
• Lipids and liver markers on longer use.
• A specific and serious one: signs of venous thromboembolism (leg swelling, chest pain, breathlessness) — tamoxifen raises clot risk, which is its most important adverse effect.

Stopping is not itself dramatic — the drug clears over a week or more given its long half-life. The real question is what the axis does afterward: a recovery attempt either succeeded in restarting endogenous production or it did not, and that outcome is visible only on bloodwork weeks later, not from how stopping feels. Lingering effects are uncommon; the thrombosis risk falls once the drug is gone.

US: prescription-only (not scheduled). Grey-market "research liquid" is ubiquitous and variable.

• Tamoxifen and pregnancyBreast · 2004
• [Tamoxifen, a high-potential molecule to treat all centronuclear myopathies]Med Sci (Paris) · 2024
• TamoxifenNurse Pract Forum · 1993
• Crosstalk of methylation and tamoxifen in breast cancer (Review)Mol Med Rep · 2024
• Individualization of tamoxifen therapy: much more than just CYP2D6 genotypingCancer Treat Rev · 2015
• Adducts and tamoxifenSemin Oncol · 1997
• Tamoxifen in men: a review of adverse eventsAndrology · 2016
• Tamoxifen and CYP2D6: a contradiction of dataOncologist · 2012
• Tamoxifen and the female reproductive tractExpert Opin Pharmacother · 2001
• [Tamoxifen flare]Zentralbl Gynakol · 1994
• Use of tamoxifen before and during pregnancyOncologist · 2011
• Tailored Tamoxifen Treatment for Breast Cancer Patients: A PerspectiveClin Breast Cancer · 2015